The global ADME/Tox market is projected to reach US$6.2 billion by 2016. This is due in no small part to the fact that most drugs that fail in the clinical development stage do so because of ADME-tox issues. Because failure at or after the clinical trial phase can be economically devastating, many companies are applying ADME-tox technology early in the drug discovery process to eliminate poor candidates before reaching clinical trials.
ADMEcell’s lead product, the CacoReady™ Kit brings an innovative tool for evaluating the intestinal absorption of compounds to the North American market. The kit offers savings of both cost and time, and is both easy to use and compatible with automation, in support of high-throughput needs. Subsequent products will share these leading-edge qualities and enable ADME-tox scientists to perform more efficient in vitro therapeutic modeling and re-profiling.